Kezar Life Sciences Acquired by Aurinia Pharma U.S. | Pharmaceuticals M&A Deal

Aurinia Pharma U.S. has completed the acquisition of Kezar Life Sciences, a pharmacy business in Delaware, for $6.955 per share plus contingent value rights. Kezar Life Sciences is a pharmaceuticals company focused on developing therapies, supporting Aurinia Pharma U.S. acquisitions in the pharmacy and broader pharmaceuticals M&A market. The merger acquisition is structured as a strategic acquisition by Aurinia Pharma U.S., with Aurinia Merger Sub, Inc. participating in the DE acquisitions process. The tender offer terms include cash consideration and one nontransferable CVR per Kezar share, with the Schedule TO amendment filed as an amendment to the original tender offer statement.